tislelizumab + cisplatin + gemcitabine + trilaciclib + influenza vaccine

This entry appears to be a composite of two unrelated medical entities: an oncology drug combination and a seasonal influenza vaccine. The oncology component consists of **tislelizumab** (a PD-1 inhibitor), **cisplatin** (a platinum-based alkylating agent), **gemcitabine** (a nucleoside analog antimetabolite), and **trilaciclib** (a CDK4/6 inhibitor). This regimen is primarily investigated for advanced or metastatic urothelial carcinoma, where trilaciclib is administered prior to chemotherapy to provide myeloprotection by transiently arresting bone marrow stem cells in the G1 phase, thereby reducing chemotherapy-induced myelosuppression. The second component, associated with **Alachua Government Services, Inc.** (a subsidiary of Sanofi), refers to a **Vero cell-derived seasonal influenza vaccine (VCIV)**. VCIV is a viral vaccine produced using Vero cell culture technology rather than traditional egg-based methods, intended to provide immunity against seasonal influenza strains. There is no known clinical product or trial that combines these four oncology drugs with an influenza vaccine as a single therapeutic intervention.

Brand names

Cosela

Other names

Vero cell-derived seasonal influenza vaccineVCIV vs EIV Seasonal Influenza Vaccine Study